nach oben

Current Hepatology Reports

Erschienen in:

09.05.2023

Role of Nutrition in Preventing Liver Disease

verfasst von: Madeleine G. Haff, Arpan Mohanty

Erschienen in: Current Hepatology Reports | Ausgabe 2/2023

Einloggen, um Zugang zu erhalten

Abstract

Purposeof Review

Nonalcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver disease, and data supporting different nutritional recommendations are varied in their methods and outcomes measures. We conducted a MEDLINE literature review to assess recent studies on the effects of diets and supplements on NAFLD.

Recent Findings

Current data support weight loss as a mechanism to halt or reverse progression of NAFLD, without a definitive answer yet on which type of diet is most effective. Research on supplements, macronutrients, and alterations of the microbiome is ongoing, and future findings may add tools that can alter the course of NAFLD.

Summary

Weight loss is currently the strongest tool to address NAFLD; howe ver, the specifics of which dietary intervention and nutritional supplements are most effective are an active area of research.

Targher G, Tilg H, Byrne CD. Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach. Lancet Gastroenterol Hepatol. 2021;6(7):578–88. https://doi.org/10.1016/S2468-1253(21)00020-0.CrossRefPubMed

•• Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023; https://doi.org/10.1097/HEP.0000000000000323. This is the latest American Association for the Study of Liver Diseases Practice Guidance on the management of NAFLD. It recommends expanded and active screening for NAFLD and diet and lifestyle interventions as key components of treatment.

Sberna AL, Bouillet B, Rouland A, et al. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO) clinical practice recommendations for the management of non-alcoholic fatty liver disease: evaluation of their application in people with type 2 diabetes. Diabet Med. 2018;35(3):368–75. https://doi.org/10.1111/dme.13565.CrossRefPubMed

Eslam M, Sarin SK, Wong VW, et al. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int. 2020;14(6):889–919. https://doi.org/10.1007/s12072-020-10094-2.CrossRefPubMed

•• Bischoff SC, Bernal W, Dasarathy S, et al. ESPEN practical guideline: clinical nutrition in liver disease. Clin Nutr Dec. 2020;39(12):3533–62. https://doi.org/10.1016/j.clnu.2020.09.001. The expansive and detailed European Society for Nutrition and Metabolism (ESPEN) 2020 practical guidelines for nutrition in liver disease analyze the evidence behind a variety of topics from the diagnostics of malnutrition to complications of medical nutrition in a spectrum of liver disease including NAFLD, acute liver failure, cirrhosis, and liver transplantation and surgery.CrossRef

Sinha A, Dutta S. Waterborne & foodborne viral hepatitis: a public health perspective. Indian J Med Res. 2019;150(5):432–5. https://doi.org/10.4103/ijmr.IJMR_1430_18.CrossRefPubMedPubMedCentral

Slot E, Zaaijer HL, Molier M, Van den Hurk K, Prinsze F, Hogema BM. Meat consumption is a major risk factor for hepatitis E virus infection. PLoS One. 2017;12(4):e0176414. https://doi.org/10.1371/journal.pone.0176414.CrossRefPubMedPubMedCentral

Barve S, Chen SY, Kirpich I, Watson WH, Mcclain C. Development, prevention, and treatment of alcohol-induced organ injury: the role of nutrition. Alcohol Res. 2017;38(2):289–302.PubMedPubMedCentral

Tantai X, Liu Y, Yeo YH, et al. Effect of sarcopenia on survival in patients with cirrhosis: a meta-analysis. J Hepatol. 2022;76(3):588–99. https://doi.org/10.1016/j.jhep.2021.11.006.CrossRefPubMed

10.

Owen OE, Trapp VE, Reichard GA, et al. Nature and quantity of fuels consumed in patients with alcoholic cirrhosis. J Clin Invest. 1983;72(5):1821–32. https://doi.org/10.1172/JCI111142.CrossRefPubMedPubMedCentral

11.

Plank LD, Gane EJ, Peng S, et al. Nocturnal nutritional supplementation improves total body protein status of patients with liver cirrhosis: a randomized 12-month trial. Hepatology. 2008;48(2):557–66. https://doi.org/10.1002/hep.22367.CrossRefPubMed

12.

Chen CJ, Wang LC, Kuo HT, Fang YC, Lee HF. Significant effects of late evening snack on liver functions in patients with liver cirrhosis: a meta-analysis of randomized controlled trials. J Gastroenterol Hepatol. 2019;34(7):1143–52. https://doi.org/10.1111/jgh.14665.CrossRefPubMed

13.

Singal AK, Bataller R, Ahn J, Kamath PS, Shah VH. ACG clinical guideline: alcoholic liver disease. Am J Gastroenterol. 2018;113(2):175–94. https://doi.org/10.1038/ajg.2017.469.CrossRefPubMedPubMedCentral

14.

Crabb DW, Im GY, Szabo G, Mellinger JL, Lucey MR. Diagnosis and treatment of alcohol-associated liver diseases: 2019 practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2020;71(1):306–33. https://doi.org/10.1002/hep.30866.CrossRefPubMed

15.

Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. Aug 2015;149(2):367–78.e5; quiz e14–5. https://doi.org/10.1053/j.gastro.2015.04.005

16.

Wong VW, Chan RS, Wong GL, et al. Community-based lifestyle modification programme for non-alcoholic fatty liver disease: a randomized controlled trial. J Hepatol. 2013;59(3):536–42. https://doi.org/10.1016/j.jhep.2013.04.013.CrossRefPubMed

17.

Swinburn BA, Sacks G, Hall KD, et al. The global obesity pandemic: shaped by global drivers and local environments. Lancet. 2011;378(9793):804–14. https://doi.org/10.1016/S0140-6736(11)60813-1.CrossRefPubMed

18.

Moosavian SP, Arab A, Paknahad Z. The effect of a Mediterranean diet on metabolic parameters in patients with non-alcoholic fatty liver disease: a systematic review of randomized controlled trials. Clin Nutr ESPEN. 2020;35:40–6. https://doi.org/10.1016/j.clnesp.2019.10.008.CrossRefPubMed

19.

• Haigh L, Kirk C, El Gendy K, et al. The effectiveness and acceptability of Mediterranean diet and calorie restriction in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis. Clin Nutr. 2022;41(9):1913–31. https://doi.org/10.1016/j.clnu.2022.06.037. This detailed systematic review and meta-analysis analyzes popular diets used in the management of NAFLD and their effect on short-term liver-related outcomes.

20.

Kouvari M, Boutari C, Chrysohoou C, et al. Mediterranean diet is inversely associated with steatosis and fibrosis and decreases ten-year diabetes and cardiovascular risk in NAFLD subjects: results from the ATTICA prospective cohort study. Clin Nutr. 2021;40(5):3314–24. https://doi.org/10.1016/j.clnu.2020.10.058.CrossRefPubMed

21.

• Asbaghi O, Choghakhori R, Ashtary-Larky D, Abbasnezhad A. Effects of the Mediterranean diet on cardiovascular risk factors in non-alcoholic fatty liver disease patients: a systematic review and meta-analysis. Clin Nutr ESPEN. 2020;37:148–56. https://doi.org/10.1016/j.clnesp.2020.03.003. This meta-analysis shows that Mediterranean diet leads to a significant decrease in serum levels of triglyceride and total cholesterol and a decrease in body weight and HOMA-IR in comparison to a control diet, in NAFLD patients even though no effects on liver enzymes were noted.

22.

Memel ZN, Wang J, Corey KE. Intermittent fasting as a treatment for nonalcoholic fatty liver disease: what is the evidence? Clin Liver Dis (Hoboken). 2022;19(3):101–5. https://doi.org/10.1002/cld.1172.CrossRefPubMed

23.

Mattson MP, de Cabo R. Effects of intermittent fasting on health, aging, and disease. Reply N Engl J Med. 2020;382(18):1773–4. https://doi.org/10.1056/NEJMc2001176.CrossRefPubMed

24.

Różański G, Pheby D, Newton JL, Murovska M, Zalewski P, Słomko J. Effect of different types of intermittent fasting on biochemical and anthropometric parameters among patients with metabolic-associated fatty liver disease (MAFLD)-a systematic review. Nutrients. 2021;14(1):19. https://doi.org/10.3390/nu14010091.CrossRef

25.

Faris M, Jahrami H, Abdelrahim D, Bragazzi N, BaHammam A. The effects of Ramadan intermittent fasting on liver function in healthy adults: a systematic review, meta-analysis, and meta-regression. Diabetes Res Clin Pract. 2021;178:108951. https://doi.org/10.1016/j.diabres.2021.108951.CrossRefPubMed

26.

Xiao Y, Liu Y, Zhao L, Zhou Y. Effect of 5:2 fasting diet on liver fat content in patients with type 2 diabetic with nonalcoholic fatty liver disease. Metab Syndr Relat Disord. 2022;20(8):459–65. https://doi.org/10.1089/met.2022.0014.CrossRefPubMed

27.

Kabisch S, Meyer NMT, Honsek C, et al. Predicting factors for metabolic non-response to a complex lifestyle intervention-a replication analysis to a randomized-controlled trial. Nutrients. 2022;14(22):4721. https://doi.org/10.3390/nu14224721.CrossRefPubMedPubMedCentral

28.

Sakane N, Kotani K, Suganuma A, et al. Effects of obesity, metabolic syndrome, and non-alcoholic or alcoholic elevated liver enzymes on incidence of diabetes following lifestyle intervention: a subanalysis of the J-DOIT1. J Occup Health. 2020;62(1):e12109. https://doi.org/10.1002/1348-9585.12109.CrossRefPubMedPubMedCentral

29.

Montemayor S, Mascaró CM, Ugarriza L, et al. Adherence to Mediterranean diet and NAFLD in patients with metabolic syndrome: the FLIPAN study. Nutrients. 2022;14(15):3186. https://doi.org/10.3390/nu14153186.CrossRefPubMedPubMedCentral

30.

• Vilar-Gomez E, Pirola CJ, Sookoian S, et al. Impact of the association between PNPLA3 genetic variation and dietary intake on the risk of significant fibrosis in patients with NAFLD. Am J Gastroenterol. 2021;116(5):994–1006. https://doi.org/10.14309/ajg.0000000000001072. This important study provides the earliest evidence that genetic factors may modulate the effect of specific dietary nutrients on risk of fibrosis in patients with NAFLD.

31.

Ellis A, Rozga M, Braakhuis A, et al. Effect of incorporating genetic testing results into nutrition counseling and care on health outcomes: an evidence analysis center systematic review-part II. J Acad Nutr Diet. 2021;121(3):582-605.e17. https://doi.org/10.1016/j.jand.2020.02.009.CrossRefPubMed

32.

Modi AA, Feld JJ, Park Y, et al. Increased caffeine consumption is associated with reduced hepatic fibrosis. Hepatology. 2010;51(1):201–9. https://doi.org/10.1002/hep.23279.CrossRefPubMed

33.

Klatsky AL, Morton C, Udaltsova N, Friedman GD. Coffee, cirrhosis, and transaminase enzymes. Arch Intern Med. 2006;166(11):1190–5. https://doi.org/10.1001/archinte.166.11.1190.CrossRefPubMed

34.

Tverdal A, Skurtveit S. Coffee intake and mortality from liver cirrhosis. Ann Epidemiol. 2003;13(6):419–23. https://doi.org/10.1016/s1047-2797(02)00462-3.CrossRefPubMed

35.

Chen YP, Lu FB, Hu YB, Xu LM, Zheng MH, Hu ED. A systematic review and a dose-response meta-analysis of coffee dose and nonalcoholic fatty liver disease. Clin Nutr. 2019;38(6):2552–7. https://doi.org/10.1016/j.clnu.2018.11.030.CrossRefPubMed

36.

Wijarnpreecha K, Thongprayoon C, Ungprasert P. Coffee consumption and risk of nonalcoholic fatty liver disease: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2017;29(2):e8–12. https://doi.org/10.1097/MEG.0000000000000776.CrossRefPubMed

37.

Hayat U, Siddiqui AA, Okut H, Afroz S, Tasleem S, Haris A. The effect of coffee consumption on the non-alcoholic fatty liver disease and liver fibrosis: a meta-analysis of 11 epidemiological studies. Ann Hepatol. 2021;20:100254. https://doi.org/10.1016/j.aohep.2020.08.071.CrossRefPubMed

38.

Albhaisi SAM, Bajaj JS. The influence of the microbiome on NAFLD and NASH. Clin Liver Dis (Hoboken). 2021;17(1):15–8. https://doi.org/10.1002/cld.1010.CrossRefPubMed

39.

Marra F, Svegliati-Baroni G. Lipotoxicity and the gut-liver axis in NASH pathogenesis. J Hepatol. 2018;68(2):280–95. https://doi.org/10.1016/j.jhep.2017.11.014.CrossRefPubMed

40.

Musazadeh V, Roshanravan N, Dehghan P, Ahrabi SS. Effect of probiotics on liver enzymes in patients with non-alcoholic fatty liver disease: an umbrella of systematic review and meta-analysis. Front Nutr. 2022;9:844242. https://doi.org/10.3389/fnut.2022.844242.CrossRefPubMedPubMedCentral

41.

Bhatt DL, Miller M, Brinton EA, et al. REDUCE-IT USA: Results from the 3146 patients randomized in the United States. Circulation. 2020;141(5):367–75. https://doi.org/10.1161/CIRCULATIONAHA.119.044440.CrossRefPubMed

42.

Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007;369(9567):1090–8. https://doi.org/10.1016/S0140-6736(07)60527-3.CrossRefPubMed

43.

Climax J, Newsome PN, Hamza M, et al. Effects of epeleuton, a novel synthetic second-generation n-3 fatty acid, on non-alcoholic fatty liver disease, triglycerides, glycemic control, and cardiometabolic and inflammatory markers. J Am Heart Assoc. 2020;9(16):e016334. https://doi.org/10.1161/JAHA.119.016334.CrossRefPubMedPubMedCentral

44.

Bayram HM, Majoo FM, Ozturkcan A. Polyphenols in the prevention and treatment of non-alcoholic fatty liver disease: an update of preclinical and clinical studies. Clin Nutr ESPEN. 2021;44:1–14. https://doi.org/10.1016/j.clnesp.2021.06.026.CrossRefPubMed

45.

Vahid F, Rahmani D, Hekmatdoost A. The association between dietary antioxidant index (DAI) and nonalcoholic fatty liver disease (NAFLD) onset; new findings from an incident case-control study. Clin Nutr ESPEN. 2021;41:360–4. https://doi.org/10.1016/j.clnesp.2020.10.020.CrossRefPubMed

46.

Sohouli MH, Fatahi S, Sayyari A, Olang B, Shidfar F. Associations between dietary total antioxidant capacity and odds of non-alcoholic fatty liver disease (NAFLD) in adults: a case-control study. J Nutr Sci. 2020;9:e48. https://doi.org/10.1017/jns.2020.39.CrossRefPubMedPubMedCentral

47.

Perumpail BJ, Li AA, John N, et al. The Role of Vitamin E in the Treatment of NAFLD. Diseases. 2018;6(4):86. https://doi.org/10.3390/diseases6040086.CrossRefPubMedPubMedCentral

48.

Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362(18):1675–85. https://doi.org/10.1056/NEJMoa0907929.CrossRefPubMedPubMedCentral

49.

Vadarlis A, Antza C, Bakaloudi DR, et al. Systematic review with meta-analysis: the effect of vitamin E supplementation in adult patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2021;36(2):311–9. https://doi.org/10.1111/jgh.15221.CrossRefPubMed

50.

Holmer M, Lindqvist C, Petersson S, et al. Treatment of NAFLD with intermittent calorie restriction or low-carb high-fat diet - a randomised controlled trial. JHEP Rep. 2021;3(3):100256. https://doi.org/10.1016/j.jhepr.2021.100256.CrossRefPubMedPubMedCentral

51.

Simons N, Veeraiah P, Simons PIHG, et al. Effects of fructose restriction on liver steatosis (FRUITLESS); a double-blind randomized controlled trial. Am J Clin Nutr. 2021;113(2):391–400. https://doi.org/10.1093/ajcn/nqaa332.CrossRefPubMed

52.

Schmidt KA, Jones RB, Rios C, et al. Clinical intervention to reduce dietary sugar does not affect liver fat in latino youth, regardless of PNPLA3 genotype: a randomized controlled trial. J Nutr. 2022;152(7):1655–65. https://doi.org/10.1093/jn/nxac046.CrossRefPubMedPubMedCentral

53.

Ezpeleta M, Gabel K, Cienfuegos S, et al. Effect of alternate day fasting combined with aerobic exercise on non-alcoholic fatty liver disease: a randomized controlled trial. Cell Metab. 2023;35(1):56-70.e3. https://doi.org/10.1016/j.cmet.2022.12.001.CrossRefPubMed

54.

Kord-Varkaneh H, Salehi-Sahlabadi A, Tinsley GM, Santos HO, Hekmatdoost A. Effects of time-restricted feeding (16/8) combined with a low-sugar diet on the management of non-alcoholic fatty liver disease: a randomized controlled trial. Nutrition. 2023;105:111847. https://doi.org/10.1016/j.nut.2022.111847.CrossRefPubMed

55.

Barcelos STA, Silva-Sperb AS, Moraes HA, et al. Oral 24-week probiotics supplementation did not decrease cardiovascular risk markers in patients with biopsy proven NASH: a double-blind placebo-controlled randomized study. Ann Hepatol. 2023;28(1):100769. https://doi.org/10.1016/j.aohep.2022.100769.CrossRefPubMed

56.

Chong PL, Laight D, Aspinall RJ, Higginson A, Cummings MH. A randomised placebo controlled trial of VSL#3. BMC Gastroenterol. 2021;21(1):144. https://doi.org/10.1186/s12876-021-01660-5.CrossRefPubMedPubMedCentral

57.

Scorletti E, Afolabi PR, Miles EA, et al. Synbiotics alter fecal microbiomes, but not liver fat or fibrosis, in a randomized trial of patients with nonalcoholic fatty liver disease. Gastroenterology. 2020;158(6):1597-1610.e7. https://doi.org/10.1053/j.gastro.2020.01.031.CrossRefPubMed

Titel: Role of Nutrition in Preventing Liver Disease
verfasst von: Madeleine G. Haff
Arpan Mohanty
Publikationsdatum: 09.05.2023
Verlag: Springer US
Erschienen in: Current Hepatology Reports / Ausgabe 2/2023
Elektronische ISSN: 2195-9595
DOI: https://doi.org/10.1007/s11901-023-00602-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Role of Nutrition in Preventing Liver Disease

Abstract

Purposeof Review

Recent Findings

Summary

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Purposeof Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin